Bioline Rx Common Stock

Bioline Rx posts a common stock of $74M as of June 2026. That compares with $72M in the prior-year period — up 2.7% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Bioline Rx's common stock was $72M. The latest reading is $74M — a 2.7% year-over-year increase (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Common Stock is one piece of Bioline Rx's financial statement story. At $74M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for BLRX's common stock usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Bioline Rx's other metric pages and overview cover the third.

Judging Bioline Rx against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in common stock easier to interpret. Start with $74M here, then scan peer and history charts to see if the gap is persistent.